Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07
  • Cefoperazone Sodium Salt: Applied Workflows in Antibacter...

    2026-02-17

    Cefoperazone Sodium Salt: Applied Workflows in Antibacterial Research

    Principle Overview: Cefoperazone Sodium Salt in Contemporary Microbiology

    Cefoperazone (sodium salt) is a semisynthetic cephalosporin antibiotic renowned for its broad spectrum antibacterial activity and exceptional stability against β-lactamase hydrolysis. As a β-lactamase stable cephalosporin, it is particularly effective against both gram-positive and gram-negative bacilli, including clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Proteus species. The defining attribute of cefoperazone is its remarkable ability to resist hydrolysis by β-lactamases produced by gram-negative bacteria, with hydrolysis rates as low as 0.01—orders of magnitude lower than many cephalosporins. This stability ensures sustained antibacterial activity in challenging resistance environments, making it an indispensable tool for in vitro antimicrobial activity assays and translational research on gram-negative bacterial resistance.

    In pharmacokinetic studies, cefoperazone achieves high concentrations in bile and gall bladder tissues post-intravenous administration, highlighting its relevance for biliary tract infection research. Its low MIC50 against Neisseria gonorrhoeae (≤0.004–0.06 μg/ml) further positions it as a reference compound for Neisseria gonorrhoeae infection models and resistance mechanism investigations.

    APExBIO’s Cefoperazone (sodium salt) (SKU C3913) is the research-grade standard, supporting high-fidelity workflows and reproducibility in both academic and industrial microbiology settings.

    Step-by-Step Workflow: Optimizing In Vitro Antimicrobial Activity Assays with Cefoperazone

    1. Preparation of Stock Solutions

    • Solubility: Dissolve cefoperazone sodium salt at up to 20 mg/mL in DMSO (≥73 mg/mL solubility) or up to 34.6 mg/mL in water. Note its insolubility in ethanol.
    • Enhancement: For higher concentrations or rapid dissolution, gently warm and apply ultrasonic treatment. This ensures complete solubilization, minimizing particulate interference in microplate-based assays (Optimizing In Vitro Assays with Cefoperazone).
    • Storage: Store lyophilized powder at -20°C. Use freshly prepared solutions for best activity and avoid long-term storage of working stocks.

    2. Broth Microdilution Protocol

    • Media Selection: Mueller-Hinton broth is the gold standard for microdilution assays, supporting a wide range of gram-negative and gram-positive isolates (Cullmann et al., 1982).
    • Inoculum Preparation: Standardize to 5 × 105 CFU/mL for reproducibility.
    • Serial Dilution: Prepare twofold serial dilutions of cefoperazone sodium salt in microtiter plates (final volume: 100 μL per well).
    • Incubation: Incubate plates at 37°C for 16–20 hours.
    • Readout: Define MIC as the lowest concentration with no visible turbidity. For resistant strains, extend the concentration range to fully capture the breakpoint.

    3. β-Lactamase Stability and Cephalosporinase Interaction Studies

    • β-Lactamase Challenge: Co-incubate test strains with known β-lactamase producers. Cefoperazone’s low hydrolysis rates (as low as 0.01 relative to other cephalosporins) provide a stringent test for β-lactamase stability.
    • Enzyme Interaction: Quantify hydrolysis via spectrophotometric β-lactam ring assays or HPLC, comparing with alternative cephalosporins for benchmarking (Cefoperazone: β-Lactamase-Stable Cephalosporin).

    4. Advanced: Biliary Tract and Neisseria Models

    • Biliary Tract Models: Leverage pharmacokinetic data by modeling cefoperazone concentrations in hepatic cell lines or ex vivo gall bladder tissue cultures, emulating clinical exposure scenarios.
    • Neisseria gonorrhoeae Assays: Use low-MIC strains to assess potency and resistance emergence. Cefoperazone’s documented MIC50 (≤0.004–0.06 μg/ml) ensures sensitivity for high-resolution resistance mapping (Leveraging β-Lactamase-Stable Cephalosporins).

    Advanced Applications & Comparative Advantages

    Cefoperazone sodium salt is more than a broad spectrum antibacterial agent—it is a research enabler for challenging resistance scenarios and mechanistic studies. Notably, Cullmann et al. (1982) compared cefoperazone against other recently developed β-lactams (e.g., mezlocillin, cefuroxime, moxalactam, and thienamycin derivatives) in 335 clinical isolates of ampicillin-resistant Enterobacteriaceae and found:

    • Broad Efficacy: Cefoperazone demonstrated mid-range MIC values, outperforming mezlocillin and cefuroxime, and providing a robust option for strains with various resistance backgrounds.
    • Resistance Benchmarking: Its activity, though marginally lower than thienamycin against certain strains, was stable in the presence of β-lactamase-producing gram-negative bacilli, confirming its value in studies of enzymatic resistance mechanisms.
    • Pharmacodynamic Modeling: High biliary excretion and tissue concentrations support translational research in hepatic and gastrointestinal infection models, distinguishing cefoperazone from other cephalosporins with less favorable pharmacokinetics.

    Complementing these findings, the article Cefoperazone Sodium Salt: β-Lactamase-Stable Broad-Spectrum Efficacy establishes cefoperazone’s high β-lactamase stability as essential for current resistance mechanism research, while Optimizing In Vitro Assays with Cefoperazone details workflow enhancements that ensure assay reproducibility and sensitivity—both serving as complementary guides to the protocol outlined here.

    Troubleshooting & Optimization Tips

    Common Issues and Solutions

    • Incomplete Dissolution: If cefoperazone sodium salt appears cloudy or fails to dissolve fully, warm the solution gently (37°C) and apply ultrasonication. Avoid vigorous vortexing, which can denature the β-lactam core.
    • Loss of Activity: Always prepare fresh working solutions. Cefoperazone solutions degrade over days, especially at room temperature, leading to underestimated MICs or false resistance.
    • Variable Results in β-Lactamase Assays: Confirm enzyme activity with positive controls and calibrate spectrophotometric assays to the specific absorbance of cefoperazone’s β-lactam ring. Cross-validate with HPLC when working with complex samples.
    • Matrix Interference: In bile or serum-spiked assays, adjust for protein binding and matrix effects using parallel blank controls. This is especially relevant for biliary tract infection research.

    Best Practices for Reproducibility

    • Batch Consistency: Use APExBIO’s validated lots for consistent performance across replicates and research groups.
    • Documentation: Record solvent, concentration, lot number, and preparation method for each experiment. This facilitates troubleshooting across multi-site studies.
    • Cross-Referencing Literature: Benchmark findings against published MIC ranges (e.g., Cullmann et al., 1982) to identify outliers and protocol deviations early.

    Future Outlook: Cefoperazone in Next-Generation Resistance Research

    The landscape of gram-negative resistance is evolving rapidly, with new β-lactamase variants and genetic determinants emerging worldwide. Cefoperazone’s robust hydrolysis resistance and broad-spectrum efficacy position it as an anchor compound for future resistance mechanism studies and high-throughput screening. Ongoing work is extending its use in:

    • High-Content Screening: Automated platforms now employ cefoperazone as a control for β-lactamase-stable cephalosporins in compound libraries and clinical isolate panels.
    • Translational Infection Models: Its pharmacokinetic profile enables more realistic in vitro-to-in vivo correlation, particularly for biliary tract infection research and Neisseria gonorrhoeae infection models.
    • Comparative Genomics: Large-scale studies are mapping cefoperazone susceptibility across thousands of clinical genomes to unravel the molecular underpinnings of gram-negative bacterial resistance.

    As highlighted in Cefoperazone: Benchmarks for Broad-Spectrum Resistance Research, these applications are setting new standards for reproducibility and translational relevance in microbiology.

    Conclusion

    Cefoperazone (sodium salt) from APExBIO is a cornerstone for modern antimicrobial research, offering robust β-lactamase stability, broad-spectrum efficacy, and workflow flexibility for the most demanding experimental models. By following the outlined protocols, leveraging troubleshooting guidance, and drawing on comparative literature, researchers can maximize reproducibility and advance the scientific understanding of resistance mechanisms. For detailed product specifications and ordering, visit the Cefoperazone (sodium salt) product page.